Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.70 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.66 |
| ▸ | MDH1 | P40925 | 5/20 | 0.65 |
| ▸ | MDH2 | P40926 | 5/20 | 0.65 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295580 | 0.89 | MDH1 (0.80) | HIF1AEPAS1MDH1MDH2HCAR2 | |
| SCHEMBL4295568 | 0.81 | HIF1A (0.73) | HIF1AEPAS1MDH1MDH2HCAR2 | |
| SCHEMBL2954418 | 0.80 | HIF1A (1.00) | HIF1AEPAS1MDH1MDH2HCAR2 | |
| SCHEMBL30460318 | 0.80 | HIF1A (1.00) | HIF1AEPAS1MDH1MDH2HCAR2 | |
| SCHEMBL20495308 | 0.79 | MDH1 (1.00) | HIF1AEPAS1MDH1MDH2ALDH1A1 | |
| SCHEMBL4299455 | 0.79 | HIF1A (0.66) | HIF1AEPAS1HCAR2SMN1; SMN2NR4A2 | |
| SCHEMBL3987191 | 0.77 | HCAR2 (1.00) | HIF1AEPAS1HCAR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4301174 | 0.76 | HIF1A (1.00) | HIF1AEPAS1MDH1MDH2EP300 | |
| SCHEMBL21631188 | 0.76 | MDH2 (1.00) | HIF1AEPAS1MDH1MDH2ALDH1A1 | |
| SCHEMBL417809 | 0.75 | HCAR2 (0.71) | HIF1AEPAS1HCAR2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | claimed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | HIF1A 2/4885EPAS1 14/4885MDH1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.